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Background:We aimed to examine whether serum levels of asymmetric dimethylarginine (ADMA), an endoge-
nous inhibitor of nitric oxide synthase, and C-reactive protein (CRP) are associated with the risk of developing
metabolic syndrome in middle-aged men.
Methods: In this longitudinal study, serum ADMA and CRP levels were measured in Japanese men without
metabolic syndrome, which was diagnosed according to the currently accepted uniﬁed criteria. The subjects
were followed-up for amaximumof four years to determine new-onsetmetabolic syndrome. A Cox proportional
hazards model with adjusting for potential confounders was applied to determine the hazard ratio (HR) for
developing metabolic syndrome according to serum levels of ADMA and CRP, considered either alone or in
combination.
Results: Of the 848 subjects (mean age, 43 ± 6 years), 100 subjects developedmetabolic syndrome. High ADMA
levels (≥0.45 μmol/L) alone did not show a signiﬁcant HR for developing metabolic syndrome, while high
CRP levels (≥0.3 mg/L) did (HR 1.75, 95% CI 1.12–2.74). The combination of high levels of both CRP and ADMA
had a high HR (2.09, 95% CI 1.12–3.76) as compared to low levels of both markers. In contrast, the HR was not
signiﬁcant in the combination of high CRP and low ADMA levels, as well as low CRP and high ADMA levels.
Conclusions: Serum CRP, but not ADMA, levels were associated with the risk of metabolic syndrome. Neverthe-
less, the risk ofmetabolic syndrome could be predictedmore reliably by considering these twomarkers together
rather than CRP alone.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Metabolic syndrome is a cluster of multiple cardiometabolic risk fac-
tors including central obesity, elevated blood pressure (BP), elevated
glucose levels, and dyslipidemia. The occurrence ofmetabolic syndrome
is therefore a high-risk condition for the incidence of cardiovascular
disease (CVD) [1]. From the viewpoint of primary prevention of CVD,
it is important not only to clarify its pathophysiological mechanisms
but also to seek useful markers for identifying individuals at risk of de-
veloping metabolic syndrome.
Nitric oxide (NO) is synthesized from its precursor L-arginine
mainly in the vascular endothelium by NO synthase. NO regulates
antiatherogenic actions of the endothelium such as vasodilation andability and freedom from bias of
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d Ltd. This is an open access article uninhibition of cellular adhesion [2]. In addition to these effects, NO may
exert a favorable impact on lipidmetabolism, fat accumulation, and glu-
cose metabolism including insulin sensitivity [3]. These ﬁndings raise
the possibility that NO homeostasis may play a role in preventing met-
abolic syndrome. Recently, researchers have focused on asymmetric
dimethylarginine (ADMA), a methylated form of L-arginine, because
it functions as an endogenous inhibitor of NO synthase and can be
regarded as amarker of NOavailability. Given the possible protective ef-
fects of NO on the factors that lead to metabolic syndrome, it is hypoth-
esized that elevated ADMA increases the risk of developing metabolic
syndrome. This hypothesis is supported by the results of a previous
cross-sectional study that found plasma ADMA levels to be elevated in
individuals with metabolic syndrome [4]. However, to our knowledge,
whether ADMA predicts future development of metabolic syndrome
has not been fully investigated to date.
Inﬂammation iswell known to play a crucial role in the pathogenesis
of metabolic syndrome [5]. Previous cohort studies found C-reactive
protein (CRP), one of the major inﬂammatory markers, to predict the
risk of developingmetabolic syndrome [6,7]. Importantly, experimentalder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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and inﬂammation, i.e., ADMA induces the production of tumor ne-
crosis factor-α (TNF-α) [8], a pro-inﬂammatory cytokine, while in-
ﬂammation and oxidative stress facilitate local or systemic ADMA
accumulation [9]. However, whether the relationship between ADMA
and inﬂammation is involved in the development of metabolic syn-
drome remains unclear.
In this study, we examined the predictive value of the serum levels
of the two markers, ADMA and CRP, considered either alone or in com-
bination, for the risk of developingmetabolic syndrome in middle-aged
men.
2. Methods
2.1. Study population
This study was conducted at a precision equipment manufacturing
company in Kanagawa, Japan. Under the Industrial Safety and Health
Lawof Japan, all employers are required to conduct health examinations
of all employees at least once a year. In the baseline survey, male
workers above the age of 35 years who had received an annual health
examination in 2005 (baseline survey) were selected. Subjects diag-
nosedwithmetabolic syndrome or a history or presence of cardiovascu-
lar disease, or CRP levels ≥10.0 mg/L at baseline were excluded.
Subjects who had incomplete data at baseline as well as those who
did not receive any follow-up examinations were also excluded from
the analysis. The study protocolwas approved by the institutional ethics
board of Nippon Medical School, Tokyo, Japan, and all participants gave
written informed consent.
2.2. Baseline survey
All subjects underwent anthropometric and BP measurements
as well as blood sampling. All measurements were conducted in a
temperature-controlled room, maintained at 22 °C ±2 °C. Body mass
index (BMI) was calculated as the weight (kg) divided by the square
of the height (m2). General obesity was deﬁned as BMI ≥25.0 kg/m2.
Waist circumference was measured at the level of the umbilicus after
expiration. Brachial BP was measured using a mercury sphygmoma-
nometer by well-trained staff members while the subject was seated
and at rest for at least 5 min.
A self-reported questionnaire was used to collect data regarding
the subjects' smoking habits, frequency of alcohol intake, family history
of CVD, exercise habits and medical information, including prescribed
drugs. Subjects who smoked a cigarette at least once daily were charac-
terized as current smokers; otherwise, they were categorized as
non-smokers. Frequent alcohol intake was deﬁned as alcohol intake at
least six days a week. Regular exercise was deﬁned as continuous
exercise for at least 15 min at least three days a week for at least one
year prior to the interrogation.
2.3. Biochemical analysis
At the time of baseline survey, blood samples were obtained from
the antecubital vein after overnight fasting (≥8 h of fasting). Standard
enzymatic methods were used to measure serum levels of total choles-
terol, triglyceride, uric acid, creatinine, andplasma glucose levels. Serum
high-density lipoprotein (HDL) cholesterol levels were measured using
the directmethod. Serum CRP levels weremeasured using a latex turbi-
dimetric immunoassay (LPIA CRP-H, Mitsubishi Kagaku Iatron, Tokyo,
Japan). The lower detection limit of the CRP assay was 0.1 mg/L and
the intra-assay coefﬁcient of variation has been reported to be ≤3.4%
[10]. Hyperuricemia was deﬁned as serum uric acid levels ≥7.0 mg/dL
or under drug treatment for elevated uric acid. After the aforementioned
measurements were done, the residual sera were stored at −30 °C
for ﬁve years, and were used to measure ADMA levels as describedelsewhere [11,12]. Brieﬂy, serum ADMA levels were measured by high-
performance liquid chromatography using ortho-phthalaldehyde for
ﬂuorescence determination at a commercial laboratory (SRL Inc.,
Tokyo, Japan). The lower detection limit of this assay was 0.06 μmol/L
and the intra-assay coefﬁcient of variation was ≤3.0%. The estimated
glomerular ﬁltration rate (eGFR) was calculated according to the fol-
lowing equation, as recommended for Japanese men by the Japanese
Society of Nephrology [13]:
eGFR mL=min=1:73m2
 
¼ 193 serum creatinine mg=dLð Þ−1:094
 age yearsð Þ−0:287:
Chronic kidney disease was categorized into three groups: G1 for
eGFR ≥90, G2 for eGFR of 60–89, and G3− for eGFR b60 [14].
2.4. Deﬁnition of metabolic syndrome
Metabolic syndrome was deﬁned according to the 2009 uniﬁed
guidelines from the International Diabetes Federation Task Force on
Epidemiology and Prevention [15]. Thus, the subjects were diagnosed
with metabolic syndrome if at least three of the following ﬁve criteria
were fulﬁlled: (1) central obesity, waist circumference ≥85 cm
(for Japanese men); (2) elevated triglyceride, serum triglyceride
levels ≥150 mg/dL or under drug treatment for elevated triglycer-
ide; (3) reduced HDL cholesterol, serum HDL cholesterol levels
b40 mg/dL or under drug treatment for reduced HDL cholesterol;
(4) elevated BP, systolic BP ≥130 mm Hg, diastolic BP ≥85 mm Hg,
or under antihypertensive drug treatment; and (5) elevated fasting
glucose, fasting plasma glucose level ≥100 mg/dL or under drug treat-
ment for elevated glucose. In this study, data regarding the type of
prescribed drugs for dyslipidemia were lacking; therefore, subjects
receiving drug treatment for dyslipidemia were considered to have ele-
vated triglyceride levels.
2.5. Follow-up examinations
The outcome of this study was the development of metabolic syn-
drome. The subjects were followed-up every 12 months at the time of
annual health examinations to determine the development ofmetabolic
syndrome for a maximum period of four years (from 2006 to 2009).
Data were censored at the 4-year follow-up or if subjects were lost to
follow-up.
2.6. Statistical analysis
All statistical tests were performed using SPSS Statistics software,
version 22 (IBM Japan, Tokyo, Japan). Continuous variables with or
without a skewed distribution were expressed as the median (inter-
quartile range), or the mean ± SD, respectively. Categorical data were
expressed as percentages of the total. The baseline characteristics of
the study groups were compared using Student's t-test, analysis of var-
iance, the χ2 test, or the Kruskal–Wallis test, as appropriate. The corre-
lation between ADMA and CRP was tested by the Spearman's rank
correlation coefﬁcient. Univariate and multivariate Cox proportional
hazards models were used to calculate the hazard ratio (HR) and the
corresponding 95% CI for developingmetabolic syndrome. For Cox anal-
ysis, the subjects were ﬁrst dichotomized into low or high level groups
dependingonwhether theADMAor theCRP levelswere belowor above
the median values, respectively. They were next divided into quartiles
according to the ADMAor CRP levels. In these analyses, twomultivariate
models were applied; model 1 included ADMA and CRP categories as
explanatory variables, while model 2 further included age, general obe-
sity, hyperuricemia, chronic kidney disease stage, frequent alcohol in-
take, current smoking status, regular exercise, and family history of
CVD as explanatory variables. The subjects were also categorized into
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CRP: low levels of both, high levels of both, low ADMA and high CRP, or
high ADMA and low CRP. For this multivariate analysis, the same ex-
planatory variables as in the model 2 were used. Lastly, the HR of each
of theﬁve diagnostic conditions ofmetabolic syndrome (central obesity,
elevated BP, elevated triglyceride, reduced HDL cholesterol, and elevat-
ed fasting glucose) was determined in the multivariate Cox model. All
statistical tests were 2-sided, and p b 0.05 was considered signiﬁcant.
3. Results
Out of the 1084men initially enrolled, somewere excluded because,
at baseline, they were diagnosed with metabolic syndrome (n = 141),
or had CVD (n = 9), or had CRP levels ≥10.0 mg/L (n = 14). Others
were excluded due to incomplete records at baseline (n= 18). In addi-
tion, 54 subjectswere excluded because they did not receive any follow-
up examinations. Finally, 848 subjects (mean age 43 ± 6 years; range
35–62 years) were included in this analysis. Among the diagnostic
conditions of metabolic syndrome, the prevalence of central obesity
and elevated BP was approximately 25% in the eligible population,
while the prevalence of reduced HDL cholesterol and elevated fasting
plasma glucose was ≤10% at baseline (Table 1). The median values
that were applied to differentiate subjects into low or high level catego-
ries were 0.45 μmol/L for ADMA and 0.3 mg/L for CRP levels. A signiﬁ-
cant but weak correlation was found between ADMA and CRP levels
(Spearman's ρ= 0.20, p b 0.001). Baseline characteristics of the study
participants according to the low or high level categories of ADMATable 1
Baseline characteristics of the study participants; overall and categorized by low/high ADMA o
Variable Overall ADMA
Low (0.33-0.44 μmol/
Number of participants 848 430
ADMA, μmol/L 0.45 ± 0.05 0.41 ± 0.03
CRPa, mg/L 0.3 (0.2, 0.5) 0.2 (0.1, 0.4)
Age, years 43 ± 6 43 ± 6
BMI, kg/m2 22.9 ± 2.6 22.6 ± 2.3
Obesity, n (%) 150 (17.7) 61 (14.2)
Waist circumference, cm 81.1 ± 7.0 80.3 ± 6.1
Central obesity, n (%) 218 (25.7) 84 (19.5)
Systolic BP, mm Hg 118 ± 12 118 ± 12
Diastolic BP, mm Hg 75 ± 9 75 ± 9
Elevated BP, n (%) 212 (25.0) 103 (24.0)
Medication for elevated BP, n (%) 18 (2.1) 9 (2.1)
Total cholesterol, mg/dL 195 ± 30 196 ± 29
Triglyceridea, mg/dL 84 (60, 120) 77 (56, 114)
Elevated triglyceride, n (%) 115 (13.6) 50 (11.6)
HDL cholesterol, mg/dL 58 ± 13 59 ± 14
Reduced HDL cholesterol, n (%) 38 (4.5) 15 (3.5)
Medication for dyslipidemia, n (%) 10 (1.2) 7 (1.6)
Fasting plasma glucose, mg/dL 90 ± 10 90 ± 13
Elevated fasting plasma glucose, n (%) 63 (7.4) 35 (8.1)
Medication for elevated glucose, n (%) 5 (0.6) 5 (1.2)
Uric acid, mg/dL 5.9 ± 1.2 5.8 ± 1.1
Hyperuricemia, n (%) 154 (18.2) 49 (11.4)
Medication for hyperuricemia, n (%) 14 (1.7) 5 (1.2)
Serum creatinine, mg/dL 0.83 ± 0.35 0.81 ± 0.12
eGFR, mL/min/1.73 m2 84.0 ± 14.3 85.4 ± 14.4
CKD stage, n (%) G1 259 (30.5) 144 (33.5)
G2 572 (67.5) 281 (65.3)
G3− 17 (2.0) 5 (1.2)
Current smoking, n (%) 231 (27.2) 93 (21.6)
Frequent alcohol intake, n (%) 206 (24.3) 108 (25.1)
Regular exercise, n (%) 187 (22.1) 89 (20.7)
Family history of CVD, n (%) 193 (22.8) 81 (18.8)
aMedian (interquartile range). bp b 0.05, cp b 0.01, and dp b 0.001 between the groups. ep b 0
fStatistical analysis was not conducted because of small number of subjects in each category.
ADMA, asymmetric dimethylarginine; BMI, body mass index; BP, blood pressure; HDL, high-de
CRP, C-reactive protein; CVD, cardiovascular disease.or CRP are shown in Table 1 and those according to the quartile of
ADMA or CRP are shown in Supplemental Tables S1 and S2,
respectively.
During the total follow-up of 3119 person-years (mean follow-up
period, 3.7 years; median, 4.0 years), 43 subjects were lost to follow-
up and 100 subjects were judged to have developed metabolic
syndrome.
In the Cox proportional hazards model (Table 2) for developing
metabolic syndrome, high ADMA levels showed a signiﬁcantly high
HR, as compared with the low ADMA levels, in the univariate
model (HR 1.58, 95% CI 1.06–2.36), but the signiﬁcance was disap-
peared in either multivariate model 1 or 2. This trend was also seen
in the quartile model of ADMA. In contrast, high CRP levels showed
a signiﬁcantly high HR not only in the univariate model and multi-
variate model 1, but also in the multivariate model 2 (HR 1.75, 95%
CI 1.12-2.74). In the quartile model, the third and the highest quartiles
of CRP had a signiﬁcantly highHRboth in the univariatemodel andmul-
tivariate model 1. Further, a signiﬁcantly high HR was observed in the
highest quartile of CRP in the multivariate model 2 (HR 2.55, 95% CI
1.28–5.09).
The effects of the four combinations of low/high levels of ADMA and
CRP on the development of metabolic syndrome were next analyzed
(Table 3). The combination of high levels of both ADMA and CRP led
to a signiﬁcantly high HR as compared with the reference combination
of low levels of both markers, in the univariate model (HR 2.91, 95% CI
1.67–5.08), as well as the multivariate model (HR 2.09, 95% CI
1.16–3.76). Importantly, the combination of low ADMA and high CRPr CRP levels.
CRP
L) High (0.45–0.79 μmol/L) Low (b0.1–0.2 mg/L) High (0.3–9.9 mg/L)
418 418 430
0.49 ± 0.04d 0.44 ± 0.05 0.46 ± 0.05d
0.3 (0.2, 0.6)d 0.2 (0.1, 0.2) 0.5 (0.3, 0.9)d
43 ± 6 43 ± 6 43 ± 6
23.2 ± 2.9c 22.1 ± 2.3 23.7 ± 2.7d
89 (21.3)c 43 (10.3) 107 (24.9)d
81.9 ± 7.7d 79.1 ± 6.2 83.0 ± 7.2d
134 (32.1)d 67 (16.0) 151 (35.1)
118 ± 12 118 ± 13 118 ± 12d
76 ± 9 75 ± 9 76 ± 9
108 (26.1) 104 (24.9) 108 (25.1)
9 (2.2) 8 (1.9) 10 (2.3)
200 ± 31 195 ± 30 201 ± 30b
93 (66, 124)d 75 (53, 105) 96 (69, 132)d
65 (15.6) 32 (7.7) 83 (19.3)d
57 ± 12 61 ± 13 55 ± 13d
23 (5.5) 16 (3.8) 22 (5.1)
3 (0.7)f 4 (1.0) 6 (1.4)f
90 ± 7 90 ± 7 0.87
28 (6.7) 32 (7.7) 31 (7.2)
0 (0.0)f 2 (0.5) 3 (0.7)f
6.1 ± 1.2d 5.7 ± 1.1 6.1 ± 1.2d
105 (25.1)d 59 (14.1) 95 (22.1)c
9 (2.1) 5 (1.2) 9 (2.1)
0.86 ± 0.49 0.82 ± 0.14 0.84 ± 0.48
83.6 ± 14.2c 84.1 ± 13.7 84.0 ± 15.0
115 (27.5)e 124 (29.7) 135 (31.4)
291 (69.6) 289 (69.1) 283 (65.8)
12 (2.9) 5 (1.2) 12 (2.8)
138 (33.0)d 96 (23.0) 135 (31.4)c
98 (23.4) 118 (28.2) 88 (20.5)c
98 (23.4) 100 (23.9) 87 (20.2)
112 (26.8)c 79 (18.9) 114 (26.5)c
.05 between the groups across the CKD stages.
nsity lipoprotein; eGFR, estimated glomerular ﬁltration rate; CKD, chronic kidney disease;
Table 2
HR for developing metabolic syndrome according to dichotomized or quartile of ADMA and CRP levels.
No. of cases/at risk Univariate model Multivariate model 1a Multivariate model 2b
HR 95% CI HR 95% CI HR 95% CI
Dichotomized model
ADMA Low 40/430 1.00 Reference 1.00 Reference 1.00 Reference
High 60/418 1.58 1.06–2.36 1.41 0.94–2.12 1.23 0.81–1.87
CRP Low 31/418 1.00 Reference 1.00 Reference 1.00 Reference
High 69/430 2.30 1.50–3.51 2.18 1.42–3.35 1.75 1.12–2.74
Quartile model
ADMA Q 1 (lowest) 18/228 1.00 Reference 1.00 Reference 1.00 Reference
Q 2 22/202 1.41 0.76–2.63 1.30 0.69–2.42 1.12 0.59–2.09
Q 3 31/225 1.80 1.01–3.22 1.61 0.90–2.89 1.32 0.72–2.41
Q 4 (highest) 29/193 1.97 1.10–3.55 1.61 0.89–2.92 1.30 0.70–2.41
p = 0.015 for trend p = 0.09 for trend p = 0.37 for trend
CRP Q 1 (lowest) 11/199 1.00 Reference 1.00 Reference 1.00 Reference
Q 2 20/219 1.69 0.81–3.52 1.70 0.82–3.55 1.55 0.74–3.26
Q 3 23/182 2.41 1.18–4.95 2.30 1.12–4.74 1.94 0.93–4.02
Q 4 (highest) 46/248 3.65 1.89–7.04 3.42 1.76–6.64 2.55 1.28–5.09
p b 0.001 for trend p b 0.001 for trend p = 0.005 for trend
HR, hazard ratio; ADMA, asymmetric dimethylarginine; CRP, C-reactive protein.
a Multivariate model 1 includes categorized ADMA and categorized CRP as explanatory variables.
b Multivariate model 2 includes categorized ADMA, categorized CRP, age, general obesity, hyperuricemia, chronic kidney disease stage, frequent alcohol intake, current smoking status,
regular exercise, and family history of cardiovascular disease as explanatory variables.
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univariate model, but the signiﬁcance disappeared in the multivariate
model. The combination of high ADMA and low CRP levels did not
show signiﬁcant HR either in the univariate or in the multivariate
model.
The effects of the above combinations on the development of each
diagnostic condition of metabolic syndrome were analyzed (Table 4).
Among the ﬁve diagnostic conditions, the combination of high levels
of both markers showed a high HR only for reduced HDL cholesterol
(HR 2.25, 95% CI 1.02–5.00). In addition, a signiﬁcantly high HR for cen-
tral obesitywas foundwith the combination of low ADMAand high CRP
levels (HR 2.00, 95% CI 1.29–3.09).4. Discussion
The main ﬁndings of this study are as follows. First, high serum CRP
levels, but not ADMA levels, were signiﬁcantly associated with an in-
creased risk of metabolic syndrome. Second, only the combination of
high levels of both ADMA and CRP showed a signiﬁcantly increased
risk of metabolic syndrome among the combinations of low/high
ADMA and CRP levels. Third, a signiﬁcant association was observed
between the combination of high levels of both markers and the risk
of developing reducedHDL cholesterol among theﬁve diagnostic condi-
tions of metabolic syndrome.Table 3
HR for developing metabolic syndrome in the combination of low/high ADMA and CRP
levels.
No. of
cases/at risk
Univariate model Multivariate modela
HR 95% CI HR 95% CI
Low CRP Low ADMA 17/245 1.00 Reference 1.00 Reference
High ADMA 14/173 1.17 0.58–2.37 1.08 0.53–2.21
High CRP Low ADMA 23/185 1.88 1.003–3.51 1.58 0.84–3.00
High ADMA 46/245 2.91 1.67–5.08 2.09 1.16–3.76
HR, hazard ratio; ADMA, asymmetric dimethylarginine; CRP, C-reactive protein.
a Multivariate model includes age, general obesity, hyperuricemia, chronic kidney dis-
ease stage, frequent alcohol intake, current smoking status, regular exercise, and family
history of cardiovascular disease as explanatory variables.The ﬁnding of a signiﬁcant association between CRP levels and
the risk of metabolic syndrome is consistent with that reported in
previous epidemiological studies [6,7]. Increased visceral adiposity in-
creases the secretion of pro-inﬂammatory cytokines such as TNF-α
and interleukin-6 [16,17]. TNF-α reduces insulin sensitivity [16,18,19],
which may in turn impair blood glucose and BP control. These pro-
inﬂammatory cytokines also produce CRP in the liver [20] and adipo-
cytes [21]. Our present ﬁnding for the association between CRP levels
and the risk of developing metabolic syndrome may be explained by
these pathophysiological mechanisms.
NO is reported to have protective effects against developing each
diagnostic condition of metabolic syndrome through several mecha-
nisms, such as vascular smoothmuscle relaxation, mitochondrial prolif-
eration and activation, improving insulin sensitivity, and inhibiting de
novo fatty acid synthesis and decreasing acetyl-CoA carboxylase activi-
ty [3]. Therefore, given the function of ADMA as an NO synthase inhibi-
tor, our present results indicating a signiﬁcant association between
the high ADMA levels and increased risk of metabolic syndrome seen
in the univariate model are expected ﬁndings. Nevertheless, this signif-
icance was not maintained when CRP was considered simultaneously
with ADMA in the analysis, while CRP levels were signiﬁcantly associat-
ed with the risk of metabolic syndrome. Previous reports showed
bidirectional relationship of ADMA and inﬂammatory responses [8,9].
However, in this study, only 4% (square of correlation coefﬁcient,
0.20) of the variance of ADMA levels can be explained by CRP levels,
and vice versa. These ﬁndings therefore suggest that in this study,
only a weak relationship was demonstrated between reduced NO
availability and activated inﬂammation, and the impact of reduced NO
availability on the development of metabolic syndrome is smaller than
that of activated inﬂammation. Further, the lack of data on serum
L-arginine levels in this study is thought to be the other explanation
for this negative result. Because ADMA competes with L-arginine for
binding to NO synthase, the ratio of L-arginine to ADMA is thought to
be a more reliable marker of NO availability than ADMA levels alone.
In fact, a previous epidemiological study has shown that the combined
analysis of L-arginine and ADMA more rigorously stratiﬁed their prog-
nosis in community-dwelling participants [22]. The relationship of the
combination of L-arginine and ADMA to the risk of metabolic syndrome
merits further investigation.
The most important and intriguing ﬁndings in this study are that
the combination of high levels of both ADMA and CRP, but not the
Table 4
Multivariate HR for developing each diagnostic condition of metabolic syndrome in the combination of low/high ADMA and CRP levels.
Central obesity
(n = 630)
Elevated BP
(n = 636)
Elevated
triglyceride
(n = 733)
Reduced HDL
cholesterol
(n = 810)
Elevated fasting glucose
(n = 785)
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Low CRP Low ADMA 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
High ADMA 0.93 0.56–1.54 0.89 0.59–1.34 0.89 0.56–1.42 0.95 0.38–2.38 0.87 0.54–1.41
High CRP Low ADMA 2.00 1.29–3.09 0.79 0.47–1.34 1.26 0.83–1.92 2.30 0.99–5.34 0.99 0.56–1.76
High ADMA 1.36 0.85–2.18 1.08 0.70–1.64 1.09 0.71–1.66 2.25 1.02–5.00 1.32 0.81–2.17
All models include age, general obesity, hyperuricemia, chronic kidney disease stage, frequent alcohol intake, current smoking status, regular exercise, and family history of cardiovascular
disease as explanatory variables.
HR, hazard ratio; ADMA, asymmetric dimethylarginine; CRP, C-reactive protein; BP, blood pressure; HDL, high-density lipoprotein.
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risk of developing metabolic syndrome. As noted above, the effect
of reduced NO availability on the development of metabolic syndrome
appeared to be smaller than that of activated inﬂammation. Neverthe-
less, these observations suggest that the coexistence of these patho-
physiological states may be needed to further predispose subjects to
an increased risk of metabolic syndrome. From a clinical perspective,
the risk of metabolic syndrome could be predicted more reliably by
measuring serum levels of CRP and ADMA together rather than CRP
levels alone.
The combination of high levels of both ADMA and CRP was signif-
icantly associated with an increased risk of reduced HDL cholesterol.
In contrast, there were no signiﬁcant associations between the com-
bination of high levels of both markers and the risk of developing any
of the other four diagnostic conditions of metabolic syndrome. These
results may be partly explained by an inadequate statistical power
due to relatively small number of the study participants in each sub-
group (n = 630 to 785). Meanwhile, the HR for central obesity
was signiﬁcantly high for the combination of low ADMA and high
CRP levels. The reasons for this unexpected ﬁnding are difﬁcult to
understand on the basis of current knowledge and need to be further
investigated.
This study has a few limitations. First, the study participants includ-
ed only middle-aged, Japanese male workers from a single company.
Therefore, it is unclear whether our results can be extrapolated to
other populations, including the elderly, women, and other ethnic
groups. Second, asmentioned above, the sample sizemay be inadequate
to examine the true association between ADMA levels and the risk of
metabolic syndrome, as well as that between the combinations of
ADMA and CRP levels and the risk of developing the diagnostic condi-
tions comprising metabolic syndrome, except for reduced HDL choles-
terol. Third, although several potential confounders were examined
in the multivariate analysis, other unknown confounders may exist,
which may have affected the results.
In conclusion, in a population of middle-aged men, high serum CRP
levels, but not ADMA levels, were associated with an increased risk of
metabolic syndrome. Furthermore, the combination of high ADMA
and high CRP levels increased the risk of metabolic syndrome, whereas
the combination of low ADMA and high CRP levels did not increase the
risk. These results suggest that activated inﬂammation rather than re-
duced NO availability may contribute to an increased risk of metabolic
syndrome, but the coexistence of these pathophysiological conditions
may further predispose to the development of metabolic syndrome.
Hence, the measurement of serum levels of both ADMA and CRP may
potentiate the predictive value for developing metabolic syndrome as
comparedwith themeasurement of CRP levels alone. In contrast, unex-
pectedly, the combination of high ADMA and high CRP levels did not
predict thedevelopment of any condition that comprisesmetabolic syn-
drome, except for reduced HDL cholesterol. Further studies are needed
to conﬁrm our present results, and address unresolved issues in this
study.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcme.2014.10.001.
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